Prospect: Information for the user
Ceftazidima Normon 2 g powder for solution for infusion EFG
ceftazidima
Read this prospect carefully before starting to use the medicine, because it contains important information for you.
1.What is Ceftazidima Normon and for what it is used
2.What you need to know before Ceftazidima Normon is administered
3.How to administer Ceftazidima Normon
4.Possible adverse effects
5.Storage of Ceftazidima Normon
6. Contents of the package and additional information
Ceftazidima Normon is an antibiotic used in adults and children (including newborns). It acts by eliminating the bacteria that cause infections. It belongs to a group of medications known ascephalosporins.
Antibiotics are used to treat bacterial infections and do not work for viral infections such as the flu or a cold. It is essential to follow the instructions regarding dosage, administration interval, and treatment duration as indicated by your doctor. Do not store or reuse this medication. If you have any leftover antibiotic after treatment, return it to the pharmacy for proper disposal. Do not dispose of medications through the drain or trash. |
Ceftazidima Normon is used to treat severe bacterial infections in:
Ceftazidima Normon may also be used:
to treat patients with low white blood cell count (neutropenia) and fever due to a bacterial infection.
You should not be given this medicine:
♦Inform your doctor beforestarting treatment withCeftazidima Normonif you think this affects you. Do not takethis medicine.
Warnings and precautions
While you are being given this medicine, be aware of certainsymptoms such as allergic reactions, nervous system disorders and gastrointestinal disorders, such as diarrhea. This will reduce the risk of possible problems. See (Be aware of these symptoms) in section 4. If you have ever had an allergic reaction to other antibiotics, you may also be allergic to this medicine.
Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized pustular psoriasis (AGPP) have been reported in association with ceftazidime treatment. Seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
If you need blood or urine tests
Ceftazidima Normon may affect the results of blood glucose tests and a blood test known as theCoombs test.If you are having tests:
♦Inform the person taking the samplethat you have been givenceftazidime.
Use of Ceftazidima Normon with other medicines
Inform your doctor if you are using, have used recently or may need to use any other medicine.
You should not be given this medicine without talking to your doctor if you are also taking:
♦Inform your doctorif this affects you.
Pregnancy and breastfeeding
Inform your doctor before you are giventhis medicine:
Your doctor will assess the benefit of treating you withthis medicineagainst the risk to the baby.
Driving and operating machinery
Ceftazidima Normonmay cause side effects, such as dizziness, that affect your ability to drive.
Do not drive or operate machinery unless you are sure it does not affect you.
Ceftazidima Normon contains sodium.
This medicine contains 104.15 mg (4.53 mmol) of sodium (main component of table salt/for cooking) per vial. This is equivalent to 5.2% of the maximum daily intake for an adult.
This medication is usually administered by a doctor or nurse.It is administered as anintravenous infusion.
The medication is reconstituted by the doctor, pharmacist, or nurse using an appropriate infusion fluid.
Recommended dose
The correct dose of this medication for you will be decided by your doctor and depends on: the severity and type of infection, if you are being treated with other antibiotics, your weight and age, and your renal function.
Newborn babies (0-2 months)
For every 1 kg of the baby's weight, 25 to 60 mg of this medication will be administered per day, divided into two doses.
Babies (over 2 months) and childrenwho weigh less than 40 kg
For every 1 kg of the baby's or child's weight,100 to150 mg of this medication will be administered per day, divided into three doses. Maximum 6 g per day.
Adults and adolescentswho weigh 40 kg or more
1 g to 2 g of this medication, three times a day. Maximum9 gper day.
Patients over 65 years old
The usual daily dose should not exceed 3 g per day, especially if you are over 80 years old.
Patients with kidney problems
You may be administered a different usual dose. Your doctor will decide how much you need of this medication, depending on the severity of the kidney disease. Your doctor will closely monitor you and more frequent renal tests will be performed.
If you are administered more Ceftazidima Normon than you should
If you accidentally receive more than the prescribed dose, contact your doctor or the nearest hospital.
You can also call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amountadministered.
If you forgot to use Ceftazidima Normon
If you miss an injection, receive it as soon as possible. However, if it is almost time for the next injection, skip the missed injection. Do not use a double dose (two injections at once) to compensate for the missed dose. Receive the next dose at the usual time.
If you interrupt the treatment with Ceftazidima Normon
Do not stop receiving this medication unless your doctor tells you to.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Seek medical attention immediately if you notice any of the following symptoms:
Symptoms to be aware of
The following severe side effects have occurred in a small number of patients, but their exact frequency is unknown:
Rare cases of severe hypersensitivity reactions with severe skin rash have been reported, which may be accompanied by fever, fatigue, facial or lymph node swelling, increased eosinophils (a type of white blood cell), liver, kidney, or lung dysfunction (a reaction known as DRESS syndrome)
♦ Contact your doctor or nurse immediately if you experience any of these symptoms.
Common side effects
May affect1 in 10people:
♦ Inform your doctorif any of these side effects concern you.
Common side effects that may appear in blood tests:
Uncommon side effects
May affect1 in 100people:
♦ Inform your doctorif you experience any of them.
Uncommon side effects that may appear in blood tests:
May affect 1 in 10,000 people:
Other side effects
Other side effects that have occurred in a small number of patients, but whose exact frequency is unknown:
Other side effects that may appear in blood tests:
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for the Pharmacovigilance of Medicines for Human Use: https//www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Store below25 °C.
Store in the original packaging to protect it from light.
Do not use this medication after the expiration date that appears on the packaging after CAD.The expiration date is the last day of the month indicated.
From a microbiological standpoint, the product should be used immediately. If not used immediately, the maximum validity period once the injectable has been reconstituted with the indicated volume of diluent is 8 hours at 25 °C and 24 hours at a temperature between 2 °C-8 °C.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.
Composition ofCeftazidima Normon
The active ingredient is ceftazidima. Each vial contains 2g ofceftazidima(as pentahidrato).
As an excipient, it contains anhydrous sodium carbonate.
Appearance of the product and contents of the packaging
The packaging of Ceftazidima Normon2 gpowder for solution for infusioncontains a 20 ml capacity vial, with 2 g of ceftazidima powder. It is presented in packaging of 1 vial or 50 vials (clinical packaging).
Holder of the marketing authorization and responsible for manufacturing
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (Spain)
Date of the last review of thisleaflet:October 2024
The detailed and updated information of this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.